COMPASS study

JRCT ID: jRCT1050240216

Registered date:17/12/2024

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: Eosinophilic Chronic Rhinosinusitis
• Date of first enrollment: 26/12/2024
• Target sample size: 200
• Study type: Observational

Outcome(s)

• Primary Outcome: Proportion of patient who are satisfied with current ECRS treatment

Secondary Outcome

1: Mean SNOT-22 score (total and each subdomain score)
-Proportion of patients with each category of SNOT-22 total score
-Proportion of patients with each category of SNOT-22 subdomain score
-Proportion of patients with each SNOT-22 cough score
2: Proportion of patients with not well-controlled asthma (ACT <20)
3: Proportion of patient who are satisfied with current ECRS treatment by biologics use/non biologics use
-Mean SNOT-22 score (total and each subdomain score) by biologics use/non-biologics
-Proportion of patients with each category of SNOT-22 total score by biologics use/non-biologics
-Proportion of patients with each category of SNOT-22 subdomain score by biologics use/non-biologics
-Proportion of patients with each SNOT-22 cough score by biologics use/non-biologics
-Proportion of patients with not well-controlled asthma (ACT <20) by biologics use/non-biologics

Key inclusion & exclusion criteria

• Age minimum: >= 18age old
• Age maximum: Not applicable

Include criteria

1. Provision of signed informed consent on the website
2. Aged >=18 years at the time of answering the web survey
3. History of ECRS diagnosis more than 3 months prior to the time of answering the web survey
4. The patients who have been receiving CRS related treatment
5. The patients who have been issued a beneficiary certificate for intractable ECRS

• Exclude criteria: None.

Related Information

• Primary Sponsor: Kawano Yoshiaki
• Source(s) of Monetary Support: AstraZeneca K.K.